Skip to Content

Term Sheet — Monday, April 27

Random Ramblings

Some assorted notes to kick off your Monday:

• Getting the gang back together: Chris Williams and Trevor Clark have quietly added some more familiar faces to Twin Brook Capital Partners, the middle-market direct lending group that they recently formed under the umbrella of Angelo Gordon & Co. Williams and Clark, you may recall, were senior managing directors with Madison Capital Partners, before being bounced in late 2013 for what parent company New York Life Investment Management termed violations of personal investment policy.

Anyway, Twin Brook recently hired Grant Haggard, a former managing director with Madison who has spent the past year with Ares Management. Also joining are ex-Madison pros Rich Christensen, Drew Guyette and Karen Saunoris. Other recent hires include Dave Gibson (ex-Goldman Sachs) and Jessica Nels (ex-BMO).

• Coming attractions: Circle Financial, the bitcoin wallet startup led by Brightcove founder Jeremy Allaire, is in the midst of raising around $40 million in new VC funding at around a $200 million pre-money valuation, according to multiple sources. Don’t be surprised if an announcement comes later this week, with both VC and Wall Street-type investors attached. The Boston-based company previously raised $26 million, including a $17 million Series B round in March 2014.

• Legal update: In 2013, we discussed how John Johnson, chief investment officer for the $6.5 billion Wyoming Retirement System, had plead guilty to insider trading charges related to the 2008 acquisition of Foundry Networks by Brocade Communications. Now comes a Reuters report that Johnson has avoided jail time by cooperating with investigators, and instead was sentenced to two years of supervised release and ordered to forfeit around $137k in ill-gotten gains and perform 50 hours of community service.

• Second act: You may remember Des Hague, who last summer lost his job a CEO of PE-backed stadium catering company Centerplate after video emerged of him kicking a Doberman puppy and then violently yanking it up by a leash. Now he’s back, leading a new investment platform called AEGIS LLC, which will focus on “promising start-ups and other business opportunities across multiple sectors.”

• Where in the world? Tonight I’ll be part of a SheStarts conversation in Boston, about how entrepreneurs can better tell their company’s story. It’s free, and you can get more info by going here.

• Morning missives: Do you have a colleague who wants to sign up for Term Sheet? Or perhaps you want to receive one of Fortune’s other morning newsletters, like The Broadsheet (focused on women in business), Data Sheet (enterprise tech) or CEO Daily (top biz stories). Now you can now do it all in one place, just by heading here.

THE BIG DEAL

• Apollo Global Management and Ares Management are considering bids for GE Capital’s mid-market lending business, according to Reuters. The deal could be worth upwards of $10 billion. Read more.

VENTURE CAPITAL DEALS

• Neuronetics Inc., a Malvern, Penn.-based maker of a stimulation therapy system for the treatment of major depression, has raised $34.3 million in Series F funding led by GE Ventures. The company previously raised over $60 million from Polaris Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures, and Onset Ventures. www.NeuroStarTMS.com

• 2C2P, a Singapore-based payment services provider, has raised $7 million in Series C funding from firms like Amun Capital and GMO Venture Partners. www.2c2p.com

• Headout, a mobile travel concierge app, has raised $1.8 million in seed funding. Version One Ventures led the round, and was joined by include 500 Startups, Nexus Venture Partners, Arena Ventures, Maiden Lane, Funders Club, Haystack Fund, Ludlow Ventures and DreamIt Ventures. Read more.

• Predixion Software, an Aliso Viejo, Calif.-based provider of cloud-based predictive analytics software, has raised an undisclosed amount of Series D funding. Software AG led the round, and was joined by return backers like GE Software Ventures. www.predixionsoftware.com

• Ratan Tatan has acquired an undisclosed stake in Chinese mobile phone maker Xiaomi. Read more.

PRIVATE EQUITY DEALS

• American Securities has agreed to acquire Royal Adhesives and Sealants LLC, a South Bend, Ind.–based maker of adhesives and sealants, from Arsenal Capital Partners. No financial terms were disclosed. www.royaladhesives.com

• Atlas Mara, the investment firm led by ex-Barclays CEO Bob Diamond, is in exclusive talks to acquire a 45% stake in Rwandan bank Banque Populaire du Rwanda for $22.5 million, according to the NY Times. Read more.

• Bregal Partners has formed Blue Harvest Fisheries LLC, via the acquisition of eight Virginia-based scallop vessels and related shore assets from the Peabody Corp. No financial terms were disclosed. www.bregalpartners.com

• Eucon, a German provider of automotive data and insurance claims management services, has raised an undisclosed amount of private equity funding from HgCapital. ww.eucon.de

• Platinum Equity has agreed to acquire Worldwide Flight Services, a France-based cargo handling company, from LBO France. No financial terms were disclosed. www.wfs.aero

• Platinum Equity has acquired Ying Shing Enterprise, a Chinese manufacturer of plastic injection molded and metal stamping components. No financial terms were disclosed. www.platinumequity.com

• Thoma Bravo and Teachers’ Private Capital have completed their previously-announced $3.6 billion take-private acquisition of Riverbed Technology, a San Francisco-based provider of application performance infrastructure. www.riverbed.com

• Vestar Capital Partners has agreed to acquire Woodstream, a Lititz, Penn.–based maker of branded pest control and lawn and garden products, from Brockway Moran & Partners and CHS Capital. No financial terms were disclosed for the deal, which is expected to close later this quarter. www.woodstream.com

IPOs

• Adaptimmune, a UK-based biotech company focused on the use of T-cell therapy to treat cancer and infectious disease, has set its IPO terms to 9.375 million shares being offered at between $15 and $17 per share. It would have a fully-diluted market cap of around $1.1 billion, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol ADAP, with BofA Merrill Lynch, Cowen & Co. and Leerink Partners serving as lead underwriters. The company last year raised $104 million in Series A funding, which followed up a strategic collaboration and licensing agreement with GlaxoSmithKline (LSE: GSK) that could be worth upwards of $350 million. Shareholders include New Enterprise Associates (16.59% pre-IPO stake), Immunocore Ltd. (7.55%), OrbiMed (7.11%), Wellington Management, Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management, Novo AS, QVT, Rock Springs Capital, VenBio Select and Merlin Nexus. adaptimmune.com

• aTyr Pharma Inc., a San Diego-based developer of Physiocrine-based therapeutics to address rare diseases, has set its IPO terms to 5.36 million shares being offered at between $13 and $15 per share. It would have an initial market cap of around $316 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol LIFE, with J.P. Morgan and Citigroup serving as lead underwriters. Shareholders include Fidelity Investments (13.56% pre-IPO stake), Polaris Partners (10.56%), Domain Associates (10.52%), Alta Partners (10.27%), Cardinal Partners (10.16%), Sofinnova Ventures (8.93%) and Baker Brothers Life Sciences (8.93%). T. Rowe Price, Federated Investors, Deerfield Management, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare. www.atyrpharma.com

• Azure Midstream Partners LP, a Dallas-based master LP focused on acquiring and operating midstream energy infrastructure located in unconventional resource basins in North America, has withdrawn registration for a $175 million IPO. No explanation was given. It plans to trade on the NYSE under ticker symbol AZUR, with Citigroup and BofA Merrill Lynch serving as underwriters.

• Collegium Pharmaceuticals Inc., a Canton, Mass.-based developer of abuse-deterrent treatments for chronic pain, has set its IPO terms to 5.8 million shares being offered at between $12 and $14 per share. It would have an initial market cap of around $256 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol COLL, with Jefferies and Piper Jaffray serving as lead underwriters. Collegium Pharma has raised around $77 million in VC funding, including a $50 million round earlier this month. Shareholders include Longitude Capital Partners (22.37% pre-IPO stake), Skyline Ventures (20.04%), Frazier Healthcare (12.44%), TPG Biotech (8.68%), Boston Millennia Partners (7.77%) and RA Capital (6.08%), Adage Capital Management, Rock Springs Capital, EcoR1 Capital, Eventide Asset Management and Aperture Venture Partners. www.collegiumpharma.com

 KloxTechnologies Inc., a Quebec-based drug company focused on developing treatments for skin and soft tissue disorders, has set its IPO terms to 4.8 million shares being offered at between $13 and $15 per share. It would have an initial market cap of around $353 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol KLOX, with UBS serving as lead underwriter. kloxtechnologies.com

• Nutanix, a San Jose, Calif.-based provider of datacenter infrastructure solutions, is interviewing banks to lead an IPO that could come later this year, according to Reuters. The company most recently raised VC funding last summer at a valuation north of $2 billion. Investors include Morgan Stanley Expansion Capital, Greenspring Associates, Riverwood Capital, SAP Ventures, Lightspeed Venture Partners, Khosla Ventures and Battery Ventures. Read more.

EXITS

• Celgene Corp. (Nasdaq: CELG) has agreed to acquire Quanticel Pharmaceuticals Inc., a San Francisco–based developer of cancer drugs, for upwards of $485 million (including a $100m upfront payment). Quanticel investors include Versant Ventures. www.celgene.com

OTHER DEALS

• Applied Materials Inc. (Nasdaq: AMAT) has abandoned its $10 billion agreement to acquire rival chip-making equipment company Tokyo Electron Inc. (Tokyo: 8035). The deal was originally struck in late 2013, but faced U.S. regulatory opposition. Read more.

• Cap Gemini (Paris: CAP) has agreed to acquire iGate Corp. (Nasdaq: IGTE), a Bridgewater, N.J.-based provider of IT outsourcing solutions, for around $4 billion, or $48 per share (4.69% premium over Friday’s closing price). Read more.

• Charter Communications (Nasdaq: CHTR) reportedly is mulling a bid to acquire rival Time Warner Cable (NYSE: TWC), in the aftermath of Comcast’s failed attempt. Charter originally had offered to buy Time Warner Cable last January for $37.3 billion, before being trumped by the Comcast bid. Read more.

• EDF (Paris: EDF) is seeking a buyer for its minority stake in Austrian regional utility Energie Steiermark, according to a local media report. The deal could be worth between €270 million and €340 million. www.edf.fr

• HSBC is considering a spin-off of its British retail banking unit, according to The Sunday Times. The business is valued at around $30 billion. Read more.

• Royal Bank of Scotland (LSE: RBS) has sold another portfolio of North American loans to Japan’s Mizuho. The deal involves around $5.6 billion of loans, and will net RBS $500 million in cash (resulting in a $30m loss for the bank). Read more.

• Swedish Orphan Biovitrum (Oslo: SOBI), a Swedish maker of medicines for rare diseases, said that it has received a takeover offer from an undisclosed buyer. The company has a current market cap of around $3.35 billion. Read more.

FIRMS & FUNDS

• TPG Capital has closed its third growth equity fund with over $3 billion in capital commitments.  www.tpggrowth.com

• Whitecap Venture Partners, a Canadian VC firm focused on early-stage opportunities, has held a C$70 million first close on its third fund (total target is upwards of C$100m). Limited partners include Kensington Venture Fund and Bank of Montreal.  www.whitecapvp.com

MOVING IN, UP, ON & OUT

• Harvest Partners SCF, a non-control private equity group, has made three new hires: Steve Duke as a principal (ex-CCMP Capital Partners), Caldwell Zimmerman as an associate (ex- Arsenal Capital Partners) and April Blackmon Meyer as a marketing associate (ex- JAT Capital Management). www.hp-scf.com

Andy Moser has left Salus Capital, in the wake of the distressed lender’s $250 million loan to RadioShack Corp., according to Bloomberg. Salus owner Harbinger Group is reviewing strategic options for the business. Read more.

Share today’s Term Sheet:
http://fortune.com/2015/04/27/term-sheet-monday-april-27